Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.40 |
| ▸ | DRD3 | P35462 | 10/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584447 | 0.86 | BACE1 (0.40) | HTR6DRD3DRD2BACE1CYP3A4 | |
| SCHEMBL6582959 | 0.73 | HTR6 (0.40) | HTR6DRD3DRD2BACE1CYP3A4 | |
| SCHEMBL6214583 | 0.69 | BACE1 (0.41) | HTR6BACE1FABP4HDAC1HDAC6 | |
| SCHEMBL5201525 | 0.67 | KDM4E (0.51) | HTR6BACE1CYP3A4FABP4HDAC1 | |
| SCHEMBL30895925 | 0.67 | KDM4E (0.51) | HTR6BACE1CYP3A4FABP4HDAC1 | |
| SCHEMBL3130145 | 0.67 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL548190 | 0.67 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL6797112 | 0.65 | GAA (0.39) | DRD2 | |
| SCHEMBL6215672 | 0.64 | FABP4 (0.43) | HTR6BACE1CYP3A4FABP4 | |
| SCHEMBL3136218 | 0.63 | P2RX7 (0.46) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743818-B2 | TREATING ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-06-01 | — | — | US | disclosed |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | PEGLION JEAN-LOUIS (FR) | 2003-02-13 | — | — | US | disclosed |
| US-6452015-B2 | FOR TREATMENT OF ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | HRH4, HTR4, CNR1 | HTR6 160/4885DRD3 462/4885DRD2 437/4885 |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | CYP2W1, HRH4, CNR1 | HTR6 77/4885DRD3 575/4885DRD2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.